1. Revealing the therapeutic targets and molecular mechanisms of emodin-treated coronavirus disease 2019 via a systematic study of network pharmacology
   Hai-Xia Du et al, 2021, Aging CrossRef
2. MYD88 L265P Mutation Detection by ddPCR: Recommendations for Screening and Minimal Residual Disease Monitoring
   Daniela Drandi et al, 2023, Clinical Applications of Nucleic Acid Amplification CrossRef
3. Correlation study of PD-L1, CD4, CD8, and PD-1 in primary diffuse large B-cell lymphoma of the central nervous system
   Bo Liu et al, 2022, Pathology - Research and Practice CrossRef
4. Utility of clinical, laboratory, and lymph node MYD88 L265P mutation in risk assessment of diffuse large B-cell lymphoma patients
   Ahmed Talaat Hanbal et al, 2024, Journal of the Egyptian National Cancer Institute CrossRef
5. In silico and in vivo analysis of TIPE1 expression in diffuse large B cell lymphoma
   Pei Shen et al, 2022, Open Life Sciences CrossRef
6. Research Topic: Measurable Residual Disease in Hematologic Malignancies. Can digital droplet PCR improve measurable residual disease monitoring in chronic lymphoid malignancies?
   Giovanni Manfredi Assanto et al, 2023, Frontiers in Oncology CrossRef
7. Oncogenic Mutations of MYD88 and CD79B in Diffuse Large B-Cell Lymphoma and Implications for Clinical Practice
   Carlo Visco et al, 2020, Cancers CrossRef
8. Good clinical response following Ibrutinib treatment of a rare case of lymphoplasmacytic lymphoma secreting IgA kappa paraprotein: A case report
   Dragomira Nikolova et al, 2024, Oncology Letters CrossRef